Top Must-Watch Stocks: Disruptive Deals, Strategic Milestones, and Emerging Market Leaders to Watch
DENVER, Colo., Jun 03, 2025- 24/7 Market News Editorial Desk (247marketnews.com)- A diverse group of emerging companies are making strategic moves that could reshape their industries. From transformative biotech partnerships and AI-powered gaming to digital asset investments and immuno-oncology breakthroughs, here are the Top Must-Watch Stocks commanding investor attention this week.
Siyata Mobile (NASDAQ:SYTA) – $160M Merger with Core Gaming AI Inches Closer
Siyata Mobile, traditionally known for its push-to-talk and cellular-based communication solutions, is on the verge of transforming itself entirely through a $160 million reverse merger with AI innovator Core Gaming. The definitive merger agreement, previously announced, is expected to close imminently—potentially creating one of the most interesting tech pivots on the NASDAQ.
Adding to the buzz, Core Gaming CEO Aitan Zacharin is scheduled to speak at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” on Wednesday, June 4, at 10:00 a.m. EDT.
Core Gaming specializes in AI-driven creative technologies, with a footprint that intersects gaming, media, and next-gen consumer entertainment. With conference topics focused on quantum computing and AI disruption, Zacharin’s panel could shed light on Core’s strategic positioning post-merger.
Watch SYTA for:
- Merger closing, which is expected to close this quarter, so any day
- AI + Gaming sector revaluation
- Zacharin’s June 4th conference presentation (live on M-Vest)
Kiora Pharmaceuticals (NASDAQ:KPRX) – Expands Global Vision Partnership, Unlocks $110M+ in Deal Potential
Kiora just signed a strategic licensing option with Senju Pharmaceutical Co. for its lead clinical-stage program KIO-301, aimed at restoring vision in patients with retinitis pigmentosa (RP). The deal covers key Asian markets, including Japan and China, and is worth up to $110 million plus royalties.
KIO-301, a “molecular photoswitch” drug that targets Retinal Ganglion Cells to restore visual signaling, is currently in a Phase 2 trial (ABACUS-2). Should Senju exercise its option after seeing topline data, Kiora will receive an upfront payment and tiered milestones.
“This option agreement represents a critical step toward establishing a long-term strategic partnership,” said Kiora CEO Brian Strem, PhD.
With additional backing from Théa (Europe), Kiora’s total strategic partnership value now tops $400M, with a cash runway into late 2027.
Watch KPRX for:
- ABACUS-2 data readout
- Option exercise by Senju
- Strategic M&A or licensing in vision therapeutics
NewGen IVF (NASDAQ:NIVF) – Bets Big on Solana, $30M Investment Signals Crypto Strategy
NewGen, an Asia-based fertility services provider, is pivoting aggressively into digital assets with plans to invest $30 million in staking Solana, funded via existing $126 million in credit lines.
This follows a $1 million Bitcoin investment in late 2024 and reflects the company’s growing conviction in blockchain as a diversification strategy and value creator.
“The decision to scale our investment from our initial $1 million Bitcoin position to this substantial $30 million Solana commitment reflects our growing conviction in digital assets as a legitimate asset class,” said CEO Alfred Siu Wing Fung.
A dedicated digital asset subsidiary is now being formed to manage staking and investment operations.
Watch NIVF for:
- Execution of Solana staking strategy
- Digital asset subsidiary formation
- Potential crypto or fintech expansion
Traws Pharma (NASDAQ:TRAW) – Cancer Drug Shows 80% ORR in Rare Disease Trial
Traws Pharma just published breakthrough efficacy data in the British Journal of Dermatology for rigosertib, a legacy oncology asset showing an 80% overall response rate (and 50% complete responses) in RDEB-associated cutaneous squamous cell carcinoma (SCC)—a rare, aggressive cancer with no approved therapies.
“These data indicate that rigosertib is a potential treatment for cutaneous SCC in RDEB patients, where there is a substantial unmet need,” said Dr. Victor Moyo, CMO Oncology.
Traws is actively seeking development and commercialization partners for rigosertib, which could offer a pathway to approval in this orphan indication.
Watch TRAW for:
- Out-licensing or partnership deals for rigosertib
- Additional oncology data or trial expansions
- Rare disease momentum in biotech
Volato (NYSE:SOAR) – Aircraft Sales Drive $25.1M Quarter, Leasing Expansion Launched
Tech-forward aviation operator Volato delivered $25.1M in Q1 revenue from its aircraft-trading program and has just launched a new third-party leasing initiative aimed at charter platforms.
The move positions Volato to become a capital-efficient aircraft lessor, creating new revenue streams and expanding its platform play.
“We’re now applying our expertise to selectively acquire charter-relevant aircraft and place them with top-tier operators,” said CEO Matt Liotta.
Watch SOAR for:
- Q2 revenue updates
- Progress on leasing rollout
- Expansion of tech-based aviation services (Mission Control, Vaunt)
Agenus (NASDAQ:AGEN) – Secures $141M Deal with Zydus for Cancer Immunotherapy BOT/BAL
Agenus has signed a $141 million collaboration with Zydus Lifesciences, transferring manufacturing assets and granting exclusive development rights for BOT/BAL, its lead immuno-oncology combo, in India and Sri Lanka.
Zydus is also investing $16 million in equity at $7.50/share, with Agenus retaining manufacturing and regulatory paths for global approval.
“This agreement is an expression of confidence in the future of Agenus,” said Dr. Garo Armen, CEO of Agenus.
The partnership aligns with U.S.-India trade priorities and supports Agenus’ near-term BLA readiness and launch strategy.
Watch AGEN for:
- Clinical trial updates for BOT/BAL
- Regulatory filings
- Expansion of BioCDMO relationships
$SYTA ‘s merger with Core Gaming is a pivotal step toward the combined companies moving forward with their mobile gaming market business model. Interested parties are encouraged to monitor $SYTA ‘s Investor Relations Portal (https://ir.siyata.net) for updates and review detailed merger math and technical analysis available at 247marketnews.com.
Investor Relations Portal (https://ir.siyata.net) for updates and review detailed merger math and technical analysis available at 247marketnews.com.
Please click on ValueScope Report for further insights.
About Core Gaming
Core Gaming is a leading developer and publisher of mobile games, known for its innovative approach to game design and user engagement. As a subsidiary of Siyata Mobile, Core Gaming is committed to delivering high-quality gaming experiences to players worldwide.
Core Gaming
For more information on Core Gaming’s latest developments and offerings, visit www.coregaming.com.
Stay Tuned:
To ensure users don’t miss future announcements, 24/7 Market News encourages users to sign up for additional information.
- $SYTA ‘s Investor Relations Portal: https://ir.siyata.net
- Follow Siyata on X: https://x.com/SiyataMobile
- Click here for $SYTA ‘s investor presentation.
For Investor Relation inquiries or to sign up for updates, please click here.
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata/
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com